Boston-based biotechnology company Ensoma has carried out another organizational restructuring as it concentrates its resources on the development of EN-374, its lead gene therapy candidate for X-linked chronic granulomatous disease (X-CGD). The move marks the second workforce reduction at the company in less than a year and includes the suspension of investment and work on programs outside its lead asset while it seeks additional financing.
In a statement confirming the changes, the company said it was aligning its operations around the continued advancement of EN-374 and the clinical validation of its technology platform for future therapeutic applications.
Company Concentrates Resources on Its Clinical-Stage Therapy
Ensoma’s only clinical-stage candidate is EN-374, an in vivo hematopoietic stem cell-directed gene insertion therapy being developed for X-CGD. The rare genetic disorder is caused by mutations in the CYBB gene and results in white blood cells being unable to effectively fight certain bacterial and fungal infections.
The therapy is designed to deliver a functional copy of the CYBB gene to patients’ stem cells using a virus-like vector, restoring the immune system to a healthy state. EN-374 is currently being evaluated in a Phase 1/2 clinical trial. In December, the company announced that the first patient had been dosed in the study.
A company spokesperson stated: “Ensoma has undertaken an organizational restructuring to align our company and resources behind the continued development of EN-374 for X-CGD and clinical validation of its platform for additional therapeutic areas.”
New Layoffs Follow Workforce Reduction Last Year
Ensoma did not disclose how many employees were affected by the latest layoffs. The company previously reduced its workforce in November, when it cut 50% of its staff in an effort to prioritize resources for the development of EN-374.
At the time, Chief Executive Officer Jim Burns said the objective was to direct resources toward areas best positioned to advance the company’s mission. Burns later indicated that 37 employees remained with the company following that restructuring.
The latest round of layoffs comes as Ensoma continues to focus on EN-374 while pausing investment and work on programs other than its lead asset as it pursues additional financing.
Research Programs Put on Hold
As part of the restructuring, Ensoma has paused several research-stage programs. These include projects focused on sickle cell disease, solid tumor immuno-oncology and heme oncology.
According to the company spokesperson, once the company raises additional funding, it will prioritize advancing the solid tumor therapy into the clinic. The programs currently on hold had remained in the research stage and had not entered clinical development.
Company Background and Funding Activities
Ensoma launched in 2021 with $70 million in funding and an agreement with Takeda to collaborate on up to five rare disease targets. Shortly before the workforce reduction announced last fall, the company raised $53 million to support clinical milestones for EN-374 and continue development of its in vivo hematopoietic stem cell engineering pipeline.
With its latest restructuring, Ensoma is concentrating its efforts on advancing EN-374 through clinical development while pausing work on other programs until additional financing is secured.
Ensoma Restructures Its Operations
Ensoma is restructuring its operations to focus more closely on EN-374, an investigational program targeting X-linked chronic granulomatous disease (X-CGD). The move reflects Ensoma’s decision to concentrate its resources around a key therapeutic program.
The Ensoma strategy highlights how biotechnology companies can prioritize their development pipelines as they move toward important clinical and regulatory milestones.
Ensoma and EN-374
EN-374 is an important part of Ensoma’s development strategy. The investigational therapy is being developed for X-linked chronic granulomatous disease, a rare inherited disorder that affects the immune system.
Patients with
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
